Metagenomics in Healthcare to Surge to $4.65 Billion by 2029
New York, Saturday, 11 October 2025.
The metagenomics in healthcare market is projected to grow at a 17.6% CAGR, reaching $4.65 billion by 2029, driven by advancements in genomic sequencing and rising demand for personalized medicine.
Market Growth Driven by Technological Advancements
The metagenomics in healthcare market is set to expand significantly, with projections indicating a growth from $2.07 billion in 2024 to $2.44 billion in 2025, representing a compound annual growth rate (CAGR) of 17.9% [1]. This impressive growth trajectory is attributed to technological advancements in genomic sequencing and bioinformatics, which are enhancing capabilities in personalized medicine and pathogen detection [1].
Key Drivers and Trends
Several factors are propelling the market’s expansion. The increasing incidence of infectious diseases, coupled with a growing demand for precision medicine, has heightened the focus on metagenomics for antimicrobial resistance surveillance [1]. Additionally, the expanding application of metagenomics in cancer research and diagnostics is driving market growth. Major trends include advancements in sequencing platforms, bioinformatics pipelines, and the integration of artificial intelligence in data analysis [1][2].
Impact on the Global Healthcare Economy
The anticipated growth of the metagenomics market holds substantial implications for the global healthcare economy. As the market reaches an estimated $4.65 billion by 2029, it is expected to revolutionize healthcare practices worldwide by enabling more precise and effective diagnostic tools and treatments [1]. This shift towards advanced diagnostics is likely to enhance patient outcomes and drive efficiencies in healthcare delivery systems globally [1].
Market Players and Future Outlook
Key players in the metagenomics in healthcare market include F. Hoffmann-La Roche AG, Eurofins Scientific, Agilent Technologies Inc., and Illumina Inc. [1]. Looking ahead, the continuous innovation in sequencing technologies and bioinformatics is poised to sustain market momentum. The integration of single-cell metagenomics and microbiome therapeutics is expected to offer new avenues for growth, further solidifying the market’s role in advancing global health initiatives [1][2].